

References

- Aasland, D., Göttinger, L., Hauck, L., Berte, N., Meyer, J., Effenberger, M., Schneider, S., Reuber, E. E., Roos, W. P., Tomicic, M. T., Kaina, B., & Christmann, M. (2019). Temozolomide Induces Senescence and Repression of DNA Repair Pathways in Glioblastoma Cells via Activation of ATR-CHK1, p21, and NF-κB. *Cancer research*, 79(1), 99–113. <https://doi.org/10.1158/0008-5472.CAN-18-1733>
- Abe, H., Natsumeda, M., Okada, M., Watanabe, J., Tsukamoto, Y., Kanemaru, Y., Yoshimura, J., Oishi, M., Hashizume, R., Kakita, A., & Fujii, Y. (2020). MGMT expression contributes to temozolomide resistance in H3K27M-Mutant diffuse midline gliomas. *Frontiers in Oncology*, 9. <https://doi.org/10.3389/fonc.2019.01568>
- Ah-Pine, F., Khettab, M., Bedoui, Y., Slama, Y., Daniel, M., Doray, B., & Gasque, P. (2023). On the origin and development of glioblastoma: multifaceted role of perivascular mesenchymal stromal cells. *Acta neuropathologica communications*, 11(1), 104. <https://doi.org/10.1186/s40478-023-01605-x>
- Ahsan, H., Asghar, M., & Malik, S. I. (2024). Potential diagnostic and drug target markers in glioblastoma. *Scientific Reports*, 14(1). <https://doi.org/10.1038/s41598-024-57752-1>
- Allen, M., Bjerke, M., Edlund, H., Nelander, S., & Westermarck, B. (2016). Origin of the U87MG glioma cell line: Good news and bad news. *Science translational medicine*, 8(354), 354re3. <https://doi.org/10.1126/scitranslmed.aaf6853>
- Arbatskiy, M., Balandin, D., Churov, A., Varachev, V., Nikolaeva, E., Mitrofanov, A., Bekyashev, A., Tkacheva, O., Susova, O., & Nasedkina, T. (2024). Intratumoral cell heterogeneity in Patient-Derived glioblastoma cell lines revealed by Single-Cell RNA-Sequencing. *International Journal of Molecular Sciences*, 25(15), 8472. <https://doi.org/10.3390/ijms25158472>
- Baker, A. M., & Johnson, R. S. (2022). Chronotherapy: Timing Temozolomide for Optimal Efficacy in Glioblastoma Treatment. *Cancer Research*

- Barcan, E. N., Duta, C., Staicu, G. A., Artene, S. A., Alexandru, O., Costachi, A., Pirvu, A. S., Tache, D. E., Stoian, I., Popescu, S. O., Tataranu, L. G., & Dricu, A. (2025). Current Research Trends in Glioblastoma: Focus on Receptor Tyrosine Kinases. *International journal of molecular sciences*, 26(8), 3503. <https://doi.org/10.3390/ijms26083503>
- Bergmann, N., Delbridge, C., Gempt, J., Feuchtinger, A., Walch, A., Schirmer, L., Bunk, W., Aschenbrenner, T., Liesche-Starnecker, F., & Schlegel, J. (2020). The intratumoral heterogeneity reflects the intertumoral subtypes of glioblastoma multiforme: a regional immunohistochemistry analysis. *Frontiers in Oncology*, 10. <https://doi.org/10.3389/fonc.2020.00494>
- Berrouet, C., Dorilas, N., Rejniak, K. A., & Tuncer, N. (2020). Comparison of Drug Inhibitory Effects (IC50) in Monolayer and Spheroid Cultures. *Bulletin of mathematical biology*, 82(6), 68. <https://doi.org/10.1007/s11538-020-00746-7>
- Bou Antoun, N., & Chioni, A. M. (2023). Dysregulated Signalling Pathways Driving Anticancer Drug Resistance. *International journal of molecular sciences*, 24(15), 12222. <https://doi.org/10.3390/ijms241512222>
- Brion, C., Lutz, S. M., & Albert, F. W. (2020). Simultaneous quantification of mRNA and protein in single cells reveals post-transcriptional effects of genetic variation. *eLife*, 9, e60645. <https://doi.org/10.7554/eLife.60645>
- Buccarelli, M., D'Alessandris, Q. G., Matarrese, P., Mollinari, C., Signore, M., Cappannini, A., Martini, M., D'Aliberti, P., De Luca, G., Pedini, F., Boe, A., Biffoni, M., Pallini, R., & Ricci-Vitiani, L. (2021). Elesclomol-induced increase of mitochondrial reactive oxygen species impairs glioblastoma stem-like cell survival and tumor growth. *Journal of experimental & clinical cancer research : CR*, 40(1), 228. <https://doi.org/10.1186/s13046-021-02031-4>
- Chen, G., Hong, X., He, W., Ou, L., Chen, B., Zhong, W., Lin, Y., & Luo, X. (2023). The construction and analysis of tricarboxylic acid cycle related prognostic model for cervical cancer. *Frontiers in Genetics*, 14. <https://doi.org/10.3389/fgene.2023.1092276>

- Chen, S., Zhang, S., Yuan, Y., Wang, Z., Li, J., Li, T., Zuo, M., Feng, W., Chen, M., & Liu, Y. (2022). Prognostic value of cuproptosis-related genes signature and its impact on the reshaped immune microenvironment of glioma. *Frontiers in Pharmacology*, 13. <https://doi.org/10.3389/fphar.2022.1016520>
- Cong, Y., Li, N., Zhang, Z., Shang, Y., & Zhao, H. (2025). Cuproptosis: molecular mechanisms, cancer prognosis, and therapeutic applications. *Journal of translational medicine*, 23(1), 104. <https://doi.org/10.1186/s12967-025-06121-1>
- Cortes Ballen, A. I., Amosu, M., Ravinder, S., Chan, J., Derin, E., Slika, H., & Tyler, B. (2024). Metabolic Reprogramming in Glioblastoma Multiforme: A Review of Pathways and Therapeutic Targets. *Cells*, 13(18), 1574. <https://doi.org/10.3390/cells13181574>
- DeCordova, S., Shastri, A., Tsolaki, A. G., Yasmin, H., Klein, L., Singh, S. K., & Kishore, U. (2020). Molecular heterogeneity and immunosuppressive microenvironment in glioblastoma. *Frontiers in Immunology*, 11. <https://doi.org/10.3389/fimmu.2020.01402>
- Debnath, J., Gammoh, N., & Ryan, K. M. (2023). Autophagy and autophagy-related pathways in cancer. *Nature reviews. Molecular cell biology*, 24(8), 560–575. <https://doi.org/10.1038/s41580-023-00585-z>
- Dymova, M. A., Kuligina, E. V., & Richter, V. A. (2021). Molecular Mechanisms of Drug Resistance in Glioblastoma. *International journal of molecular sciences*, 22(12), 6385. <https://doi.org/10.3390/ijms22126385>
- Fu, M., Xue, B., Miao, X., & Gao, Z. (2025). Overcoming immunotherapy resistance in glioblastoma: challenges and emerging strategies. *Frontiers in pharmacology*, 16, 1584688. <https://doi.org/10.3389/fphar.2025.1584688>
- Gao, J., Wu, X., Huang, S., Zhao, Z., He, W., & Song, M. (2023). Novel insights into anticancer mechanisms of elesclomol: More than a prooxidant drug. *Redox biology*, 67, 102891. <https://doi.org/10.1016/j.redox.2023.102891>

- Ghasemi, M., Turnbull, T., Sebastian, S., & Kempson, I. (2021). The MTT Assay: Utility, Limitations, Pitfalls, and Interpretation in Bulk and Single-Cell Analysis. *International journal of molecular sciences*, 22(23), 12827. <https://doi.org/10.3390/ijms222312827>
- Grochans, S., Cybulska, A. M., Simińska, D., Korbecki, J., Kojder, K., Chlubek, D., & Baranowska-Bosiacka, I. (2022). Epidemiology of Glioblastoma Multiforme-Literature Review. *Cancers*, 14(10), 2412. <https://doi.org/10.3390/cancers14102412>
- Gunasegaran, B., Ashley, C. L., Marsh-Wakefield, F., Guillemin, G. J., & Heng, B. (2024). Viruses in glioblastoma: an update on evidence and clinical trials. *BJC Reports*, 2(1). <https://doi.org/10.1038/s44276-024-00051-z>
- Fu, Q., Chen, P., Wang, Z., Liu, B., Zhou, Q., Anwar, I., & Wang, Y. (2025). The function of TRIML2 on the temozolomide resistance in glioblastoma. *Annals of medicine and surgery (2012)*, 87(2), 506–514. <https://doi.org/10.1097/MS9.0000000000002888>
- Guo, Z., Chen, D., Yao, L., Sun, Y., Li, D., Le, J., Dian, Y., Zeng, F., Chen, X., & Deng, G. (2025). The molecular mechanism and therapeutic landscape of copper and cuproptosis in cancer. *Signal Transduction and Targeted Therapy*, 10(1). <https://doi.org/10.1038/s41392-025-02192-0>
- Hegi, M. E., Diserens, A.-C., & Gorlia, T. (2021). MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. *New England Journal of Medicine*.
- Jezierzański, M., Nafalska, N., Stopyra, M., Furgoń, T., Miciak, M., Kabut, J., & Gisterek-Grocholska, I. (2024). Temozolomide (TMZ) in the Treatment of Glioblastoma Multiforme-A Literature Review and Clinical Outcomes. *Current oncology (Toronto, Ont.)*, 31(7), 3994–4002. <https://doi.org/10.3390/curroncol31070296>
- Jia, D., Wang, F., & Yu, H. (2023). Systemic alterations of tricarboxylic acid cycle enzymes in Alzheimer's disease. *Frontiers in Neuroscience*, 17. <https://doi.org/10.3389/fnins.2023.1206688>
- Kałuzińska-Kołat, Ż., Kołat, D., Kośła, K., Płuciennik, E., & Bednarek, A. K. (2023). Molecular landscapes of glioblastoma cell lines revealed a group of patients that do not benefit from WWOX tumor

suppressor expression. *Frontiers in neuroscience*, 17, 1260409.
<https://doi.org/10.3389/fnins.2023.1260409>

Kanderi, T., Munakomi, S., & Gupta, V. (2024, May 6). Glioblastoma Multiforme. *StatPearls - NCBI Bookshelf*. <https://www.ncbi.nlm.nih.gov/books/NBK558954/>

Khan, F., Ali Shah, S. Z., & Bafakeeh, O. T. (2021). Pharmacokinetics and Pharmacodynamics of Temozolomide: A Review on Current Status and Future Directions. *Pharmaceuticals*.

Kim, S., Cho, Y., Shin, Y., Yu, H. J., Chowdhury, T., Kim, S., Yi, K. S., Choi, C., Cha, S., Park, C., & Ku, J. (2023). Patient-derived glioblastoma cell lines with conserved genome profiles of the original tissue. *Scientific Data*, 10(1). <https://doi.org/10.1038/s41597-023-02365-y>

Kim, Y., Varn, F. S., Park, S. H., Yoon, B. W., Park, H. R., Lee, C., Verhaak, R. G. W., & Paek, S. H. (2021). Perspective of mesenchymal transformation in glioblastoma. *Acta neuropathologica communications*, 9(1), 50. <https://doi.org/10.1186/s40478-021-01151-4>

Kondo T. (2022). Glioblastoma-initiating cell heterogeneity generated by the cell-of-origin, genetic/epigenetic mutation and microenvironment. *Seminars in cancer biology*, 82, 176–183.
<https://doi.org/10.1016/j.semcancer.2020.12.003>

Kreisl, T. N., Kim, L., & Moore, K. (2020). Mismatch Repair Deficiency and Resistance to Temozolomide in Glioblastoma: Insights from Clinical Trials. *Clinical Cancer Research*.

Lei, Z. N., Tian, Q., Teng, Q. X., Wurpel, J. N. D., Zeng, L., Pan, Y., & Chen, Z. S. (2023). Understanding and targeting resistance mechanisms in cancer. *MedComm*, 4(3), e265.
<https://doi.org/10.1002/mco2.265>

Li, S., Bu, L., & Cai, L. (2022). Cuproptosis: lipoylated TCA cycle proteins-mediated novel cell death pathway. *Signal Transduction and Targeted Therapy*, 7(1).
<https://doi.org/10.1038/s41392-022-01014-x>

Li, H., Zhang, C., Zhu, N., Shi, Y., & Qin, L. (2025). Sensitivity of renal cell carcinoma to cuproptosis: a bioinformatics analysis and experimental verification. *Journal of Cancer*, 16(3), 952–968.
<https://doi.org/10.7150/jca.103708>

- Liu, S., Lv, S., Li, X., Lu, W., & Chen, S. (2024). The signature genes of cuproptosis associates with tumor immune microenvironment and predicts prognosis in kidney renal clear cell carcinoma. *Frontiers in Oncology*, 14. <https://doi.org/10.3389/fonc.2024.1409620>
- Liu, Y., Wu, Z., Feng, Y., Gao, J., Wang, B., Lian, C., & Diao, B. (2023). Integration analysis of single-cell and spatial transcriptomics reveal the cellular heterogeneity landscape in glioblastoma and establish a polygenic risk model. *Frontiers in Oncology*, 13. <https://doi.org/10.3389/fonc.2023.1109037>
- Loria, R., Vici, P., Di Lisa, F. S., Soddu, S., Maugeri-Saccà, M., & Bon, G. (2022). Cross-Resistance among sequential cancer therapeutics: an emerging issue. *Frontiers in Oncology*, 12. <https://doi.org/10.3389/fonc.2022.877380>
- Lou, Q. M., Lai, F. F., Li, J. W., Mao, K. J., Wan, H. T., & He, Y. (2024). Mechanisms of cuproptosis and its relevance to distinct diseases. *Apoptosis : an international journal on programmed cell death*, 29(7-8), 981–1006. <https://doi.org/10.1007/s10495-024-01983-0>
- Lu, H., Zhou, L., Zhang, B., Xie, Y., Yang, H., & Wang, Z. (2022). Cuproptosis key gene FDX1 is a prognostic biomarker and associated with immune infiltration in glioma. *Frontiers in Medicine*, 9. <https://doi.org/10.3389/fmed.2022.939776>
- Luo, D., Luo, A., Hu, S., Ye, G., Li, D., Zhao, H., & Peng, B. (2024). Genomics and proteomics to determine novel molecular subtypes and predict the response to immunotherapy and the effect of bevacizumab in glioblastoma. *Scientific Reports*, 14(1). <https://doi.org/10.1038/s41598-024-68648-5>
- Lv, H., Liu, X., Zeng, X., Liu, Y., Zhang, C., Zhang, Q., & Xu, J. (2022). Comprehensive Analysis of Cuproptosis-Related Genes in Immune Infiltration and Prognosis in Melanoma. *Frontiers in pharmacology*, 13, 930041. <https://doi.org/10.3389/fphar.2022.930041>
- Moussa, Z., Darwish, D. B., Alrdahe, S. S., & Saber, W. I. A. (2021b). Innovative Artificial-Intelligence-Based Approach for the Biodegradation of Feather Keratin by *Bacillus paramycoides*, and

- Cytotoxicity of the Resulting Amino Acids. *Frontiers in Microbiology*, 12. <https://doi.org/10.3389/fmicb.2021.731262>
- Morelli, M., Lessi, F., Barachini, S., Liotti, R., Montemurro, N., Perrini, P., Santonocito, O. S., Gambacciani, C., Snuderl, M., Pieri, F., Aquila, F., Farnesi, A., Naccarato, A. G., Viacava, P., Cardarelli, F., Ferri, G., Mulholland, P., Ottaviani, D., Paiar, F., Liberti, G., ... Mazzanti, C. M. (2022). Metabolic-imaging of human glioblastoma live tumors: A new precision-medicine approach to predict tumor treatment response early. *Frontiers in oncology*, 12, 969812. <https://doi.org/10.3389/fonc.2022.969812>
- Noch, E. K., Ramakrishna, R., & Magge, R. (2018). Challenges in the Treatment of Glioblastoma: Multisystem Mechanisms of Therapeutic Resistance. *World neurosurgery*, 116, 505–517. <https://doi.org/10.1016/j.wneu.2018.04.022>
- Nussinov, R., Yavuz, B. R., & Jang, H. (2025). Molecular principles underlying aggressive cancers. *Signal Transduction and Targeted Therapy*, 10(1). <https://doi.org/10.1038/s41392-025-02129-7>
- Ortiz, R., Perazzoli, G., Cabeza, L., Jiménez-Luna, C., Luque, R., Prados, J., & Melguizo, C. (2021). Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications. *Current neuropharmacology*, 19(4), 513–537. <https://doi.org/10.2174/1570159X18666200626204005>
- Pouyan, A., Ghorbanlo, M., Eslami, M., Jahanshahi, M., Ziaei, E., Salami, A., Mokhtari, K., Shahpasand, K., Farahani, N., Meybodi, T. E., Entezari, M., Taheriazam, A., Hushmandi, K., & Hashemi, M. (2025). Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies. *Molecular cancer*, 24(1), 58. <https://doi.org/10.1186/s12943-025-02267-0>
- Pu, J., Yuan, K., Tao, J., Qin, Y., Li, Y., Fu, J., Li, Z., Zhou, H., Tang, Z., Li, L., Gai, X., & Qin, D. (2025). Glioblastoma multiforme: an updated overview of temozolomide resistance mechanisms and strategies to overcome resistance. *Discover oncology*, 16(1), 731. <https://doi.org/10.1007/s12672-025-02567-3>

- Rahban, M., Joushi, S., Bashiri, H., Saso, L., & Sheibani, V. (2024). Characterization of prevalent tyrosine kinase inhibitors and their challenges in glioblastoma treatment. *Frontiers in Chemistry*, 11. <https://doi.org/10.3389/fchem.2023.1325214>
- Röglin, A., Böger, R., Kleinsang, F., & Hannemann, J. (2025). Identification of an appropriate reference gene for normalization of qRT-PCR expression analyses in human breast cancer cell lines: application to L-arginine depletion studies. *Journal of cancer research and clinical oncology*, 151(3), 122. <https://doi.org/10.1007/s00432-025-06165-2>
- Salehi-Shadkami, H., Sedghi, M., Tavoosi, S., Alimohammadi, M., Alimohammadi, R., Barkhordar, M., Mofayezi, A., Modaresi, M. S., Vaezi, M., Dehghanizadeh, S., Ahmadvand, M., & Khoddami, V. (2024). Effective targeting of CD19 positive primary B-ALL cells using CAR-NK cells generated with mRNA-LNPs. *bioRxiv (Cold Spring Harbor Laboratory)*. <https://doi.org/10.1101/2024.11.21.624707>
- Stupp, R., Mason, W. P., & van den Bent, M. J. (2020). Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. *New England Journal of Medicine*.
- Soni, V., Adhikari, M., Simonyan, H., Lin, L., Sherman, J. H., Young, C. N., & Keidar, M. (2021). In vitro and in vivo enhancement of temozolomide effect in human glioblastoma by Non-Invasive application of cold atmospheric plasma. *Cancers*, 13(17), 4485. <https://doi.org/10.3390/cancers13174485>
- Sowinska, W., Wawro, M., Kochan, J., Solecka, A., Polak, J., Kwinta, B., & Kasza, A. (2024). Regnase-2 inhibits glioblastoma cell proliferation. *Scientific Reports*, 14(1). <https://doi.org/10.1038/s41598-024-51809-x>
- Tarin, M., Babaie, M., Eshghi, H., Matin, M. M., & Saljooghi, A. S. (2023). Elesclomol, a copper-transporting therapeutic agent targeting mitochondria: from discovery to its novel applications. *Journal of translational medicine*, 21(1), 745. <https://doi.org/10.1186/s12967-023-04533-5>

- Tilak, M., Holborn, J., New, L. A., Lalonde, J., & Jones, N. (2021). Receptor tyrosine kinase signaling and targeting in glioblastoma multiforme. *International Journal of Molecular Sciences*, 22(4), 1831. <https://doi.org/10.3390/ijms22041831>
- Tomuleasa, C., Tigu, A., Munteanu, R., Moldovan, C., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024). Therapeutic advances of targeting receptor tyrosine kinases in cancer. *Signal Transduction and Targeted Therapy*, 9(1). <https://doi.org/10.1038/s41392-024-01899-w>
- Trejo-Solís, C., Serrano-García, N., Castillo-Rodríguez, R. A., Robledo-Cadena, D. X., Jimenez-Farfan, D., Marín-Hernández, Á., Silva-Adaya, D., Rodríguez-Pérez, C. E., & Gallardo-Pérez, J. C. (2024). Metabolic dysregulation of tricarboxylic acid cycle and oxidative phosphorylation in glioblastoma. *Reviews in the Neurosciences*, 35(7), 813–838. <https://doi.org/10.1515/revneuro-2024-0054>
- Tsui, K., Hsiao, J., Lin, L., Tsang, Y., Shao, A., Kuo, C., Chang, R., Wen, Z., & Li, C. (2023). The Cross-Communication of Cuproptosis and Regulated cell death in Human Pathophysiology. *International Journal of Biological Sciences*, 20(1), 218–230. <https://doi.org/10.7150/ijbs.84733>
- Tsvetkov, P., Coy, S., Petrova, B., Dreishpoon, M., Verma, A., Abdusamad, M., Rossen, J., Joesch-Cohen, L., Humeidi, R., Spangler, R. D., Eaton, J. K., Frenkel, E., Kocak, M., Corsello, S. M., Lutsenko, S., Kanarek, N., Santagata, S., & Golub, T. R. (2022). Copper induces cell death by targeting lipoylated TCA cycle proteins. *Science (New York, N.Y.)*, 375(6586), 1254–1261. <https://doi.org/10.1126/science.abf0529>
- Wang, Q., Wang, J., Mathur, R., Youngblood, M. W., Jin, Q., Hou, Y., Stasiak, L. A., Luan, Y., Zhao, H., Hilz, S., Hong, C., Chang, S. M., Lupo, J. M., Phillips, J. J., Costello, J. F., & Yue, F. (2025). Spatial 3D genome organization reveals intratumor heterogeneity in primary glioblastoma samples. *Science advances*, 11(11), eadn2830. <https://doi.org/10.1126/sciadv.adn2830>

- Wen, H., Qu, C., Wang, Z., Gao, H., Liu, W., Wang, H., Sun, H., Gu, J., Yang, Z., & Wang, X. (2023). Cuproptosis enhances docetaxel chemosensitivity by inhibiting autophagy via the DLAT/mTOR pathway in prostate cancer. *The FASEB Journal*, 37(9). <https://doi.org/10.1096/fj.202300980r>
- Weller, M., van den Bent, M., & Preusser, M. (2021). Standards of Care for Treatment of Glioblastoma: Current Guidelines and Emerging Therapies. *Nature Reviews Clinical Oncology*.
- Wu, W., Klockow, J. L., Zhang, M., Lafortune, F., Chang, E., Jin, L., Wu, Y., & Daldrup-Link, H. E. (2021). Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance. *Pharmacological research*, 171, 105780. <https://doi.org/10.1016/j.phrs.2021.105780>
- Xie, Y., et al. (2023). Mechanisms underlying copper-induced cell death: Implications for therapy. *Cancers*.
- Xu, C., Hou, P., Li, X., Xiao, M., Zhang, Z., Li, Z., Xu, J., Liu, G., Tan, Y., & Fang, C. (2024). Comprehensive understanding of glioblastoma molecular phenotypes: classification, characteristics, and transition. *Cancer Biology and Medicine*, 1–19. <https://doi.org/10.20892/j.issn.2095-3941.2023.0510>
- Yun, E. J., Kim, S., Hsieh, J. T., & Baek, S. T. (2020). Wnt/ β -catenin signaling pathway induces autophagy-mediated temozolomide-resistance in human glioblastoma. *Cell Death & Disease*, 11(9), 771.
- Zhang, H., et al. (2023). Cuproptosis-related genes predict prognosis and trastuzumab response in HER2-positive breast cancer. *Scientific Reports*.
- Zhao, L., Geng, R., Huang, Y., Zhang, J., Cheng, H., Zhou, C., & Wang, Y. (2023). AP2 α negatively regulates PDHA1 in cervical cancer cells to promote aggressive features and aerobic glycolysis in vitro and in vivo. *Journal of gynecologic oncology*, 34(5), e59. <https://doi.org/10.3802/jgo.2023.34.e59>

Zhou, C., Li, C., Zheng, Y., & Huang, X. (2022). Regulation, genomics, and clinical characteristics of cuproptosis regulators in pan-cancer. *Frontiers in Oncology*, 12. <https://doi.org/10.3389/fonc.2022.934076>

Zhu, S., Guo, J., Yu, L., Liu, J., Chen, J., Xin, J., Zhang, Y., Luo, J., & Duan, C. (2023). Synergistic effect of cryptotanshinone and temozolomide treatment against human glioblastoma cells. *Scientific Reports*, 13(1). <https://doi.org/10.1038/s41598-023-48777-z>